Leveraging Dissolution by Autoinjector Designs
Pharmaceutics, 2022 Chemical warfare or terrorism attacks with organophosphates may place intoxicated subjects under immediate life-threatening and psychologically demanding conditions.
Christoph Spangardt +6 more
doaj +3 more sources
Performance evaluation of an adalimumab biosimilar autoinjector and its reference device: comparative use human factors study in patients with rheumatoid arthritis and juvenile idiopathic arthritis [PDF]
Drug DeliveryA Comparative Use Human Factors study was conducted to assess whether the injection success rate (SR) with biosimilar adalimumab-fkjp (Bios-ADA) autoinjector (Hulio®) is comparable to reference adalimumab (Ref-ADA) autoinjector (Humira®), accounting for ...
Sam Moses K +1 more
doaj +2 more sources
Nurses’ perceptions on the usability of the Hyrimoz® Sensoready® autoinjector device [PDF]
Drugs in ContextBackground: Hyrimoz® (Sandoz adalimumab biosimilar) became available in the USA in July 2023, and is administered subcutaneously using a pre-filled autoinjector device, the Hyrimoz Sensoready® pen. As nurses are often responsible for training patients in
Charlotte Both +4 more
doaj +2 more sources
Human factors validation study of a disposable autoinjector (Bmab 1200 autoinjector) for subcutaneous delivery of Ustekinumab [PDF]
Drug DeliveryUstekinumab is approved for treating moderate to severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. The Bmab 1200 autoinjector is a simple, two-step device for subcutaneous ustekinumab biosimilar delivery.
Sam Moses K +2 more
doaj +2 more sources
Assessment of Flexible Dosing Volumes in an Existing Spring-Driven Autoinjector Platform [PDF]
PharmaceuticsBackground: Flexibility in dosing volume within an autoinjector platform is critical for streamlining product development, enabling dose adjustments without altering concentration.
Rozhin Derakhshandeh +3 more
doaj +2 more sources
A Human Factors Validation of a Smart Autoinjector Accessory Designed to Improve Self-Injection Outcomes and User Confidence [PDF]
Medical Devices: Evidence and ResearchStephan Wegner,1 Jana Milenkovic,1 Anthony D Andre,2 Carson P Whitaker,2 Tobias Theiler1 1Ypsomed AG, Burgdorf, Switzerland; 2Interface Analysis Associates LLC, Saratoga, CA, USACorrespondence: Stephan Wegner, Ypsomed AG, Brunnmattstrasse 6, Burgdorf ...
Wegner S +4 more
doaj +2 more sources
Patient Preferences for Self-Injectable Preventive Treatment for Migraine: A Multi-country Discrete Choice Experiment [PDF]
Neurology and TherapyIntroduction Self-injectable calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) and oral CGRP antagonists are currently available for migraine prevention.
Jaein Seo +8 more
doaj +2 more sources
Self‐Injection Satisfaction and Safety of CT‐P17 (Yuflyma), a High‐Concentration Adalimumab Biosimilar, in Patients With Crohn's Disease: A Cross‐Sectional Study [PDF]
JGH OpenBackground CT‐P17 (Yuflyma), a biosimilar to adalimumab (Humira), offers a cost‐effective alternative with improved access for individuals with immune‐mediated inflammatory diseases (IMIDs).
Fei Yang Pan +3 more
doaj +2 more sources
Frontiers in Pediatrics, 2022 BackgroundAnaphylaxis is a life-threatening event, but it is frequently undertreated in pediatric patients with food allergies. Previous studies showed that auto-injectable adrenaline (AAI) is underused by patients and parents.
Laura Polloni +9 more
doaj +1 more source
Rheumatology and Therapy, 2019 Introduction Imraldi™ is a biosimilar of the anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab and was recently approved in Europe for the treatment of various inflammatory conditions. Imraldi is administered via an autoinjector device that
Steve Fenwick +2 more
doaj +1 more source